Michael Rader

3.3k total citations · 2 hit papers
20 papers, 2.4k citations indexed

About

Michael Rader is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Rader has authored 20 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Rader's work include Bone health and treatments (7 papers), Blood disorders and treatments (6 papers) and Neutropenia and Cancer Infections (6 papers). Michael Rader is often cited by papers focused on Bone health and treatments (7 papers), Blood disorders and treatments (6 papers) and Neutropenia and Cancer Infections (6 papers). Michael Rader collaborates with scholars based in United States, United Kingdom and France. Michael Rader's co-authors include Janet E. Brown, Karim Fizazi, Carsten Goessl, Huei Wang, Piotr Milecki, Neal D. Shore, Ronaldo Damião, Michael A. Carducci, Lawrence I. Karsh and Roger Dansey and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and European Urology.

In The Last Decade

Michael Rader

19 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

2011 1.4k citations Karim Fizazi, Michael A. Carducci et al. The Lancet profile →
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Rader United States	9	1.8k	1.0k	666	463	422	20	2.4k
Ada Braun United States	22	2.7k 1.5×	754 0.7×	749 1.1×	834 1.8×	656 1.6×	63	3.2k
Richard H. De Boer Australia	15	1.7k 0.9×	669 0.7×	363 0.5×	426 0.9×	297 0.7×	48	2.1k
H.P. Sleeboom Netherlands	12	1.5k 0.8×	405 0.4×	484 0.7×	540 1.2×	334 0.8×	21	1.8k
Winnie Sohn United States	13	686 0.4×	510 0.5×	271 0.4×	173 0.4×	324 0.8×	26	1.5k
Rodolfo Bordoni United States	16	1.3k 0.7×	696 0.7×	188 0.3×	98 0.2×	131 0.3×	51	1.6k
М. Р. Личиницер United States	12	1.1k 0.6×	255 0.3×	419 0.6×	156 0.3×	284 0.7×	14	1.3k
Carles X. Raventós Spain	21	350 0.2×	850 0.8×	102 0.2×	151 0.3×	438 1.0×	73	1.4k
Rui Guo China	27	891 0.5×	634 0.6×	365 0.5×	32 0.1×	904 2.1×	93	2.2k
W.M. Sze China	19	1.5k 0.8×	992 1.0×	316 0.5×	42 0.1×	2.3k 5.3×	31	3.4k
Eirini Katodritou Greece	24	1.4k 0.8×	148 0.1×	113 0.2×	394 0.9×	102 0.2×	108	2.5k

Countries citing papers authored by Michael Rader

Since Specialization

Citations

This map shows the geographic impact of Michael Rader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Rader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Rader more than expected).

Fields of papers citing papers by Michael Rader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Rader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Rader. The network helps show where Michael Rader may publish in the future.

Co-authorship network of co-authors of Michael Rader

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Rader. A scholar is included among the top collaborators of Michael Rader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Rader. Michael Rader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Christophe Massard, Matthew R. Smith, et al.. (2014). Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. European Urology. 68(1). 42–50. 109 indexed citations

Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092. 420 indexed citations breakdown →

Stopeck, Alison, Michael Rader, David Henry, et al.. (2012). Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics. 15(4). 712–723. 48 indexed citations

Rader, Michael, Mark D. Danese, Ze Cong, et al.. (2012). Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).. Journal of Clinical Oncology. 30(5_suppl). 59–59. 1 indexed citations

Fizazi, Karim, Christophe Massard, Matthew R. Smith, et al.. (2012). Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.. Journal of Clinical Oncology. 30(15_suppl). 4642–4642. 4 indexed citations

Revicki, Dennis A., Donald E. Stull, Margaret Vernon, et al.. (2011). Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. Quality of Life Research. 21(2). 311–321. 6 indexed citations

Fizazi, Karim, Michael A. Carducci, Matthew R. Smith, et al.. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet. 377(9768). 813–822. 1377 indexed citations breakdown →

Richardson, Gary, Tudor–Eliade Ciuleanu, Luís Costa, et al.. (2011). Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.. Journal of Clinical Oncology. 29(15_suppl). 9115–9115. 2 indexed citations

Miller, Michelle & Michael Rader. (2010). Two Heads Are Better Than One: Collaborative Development of an Online Course Content Template. 1 indexed citations

10.

Rader, Michael, et al.. (2010). Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices. Community Oncology. 7(6). 273–280. 3 indexed citations

11.

Venkatakrishnan, Karthik, Michael Rader, Ramesh K. Ramanathan, et al.. (2009). Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study. Clinical Therapeutics. 31. 2444–2458. 53 indexed citations

12.

Mirtsching, B., et al.. (2007). Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy. 5. 38–39. 1 indexed citations

13.

Ozer, Howard, B. Mirtsching, Michael Rader, et al.. (2007). Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use. The Oncologist. 12(4). 484–494. 41 indexed citations

14.

Chatta, Gurkamal, Michael Rader, Chandra P. Belani, et al.. (2007). Effect of ketoconazole administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 13016–13016. 1 indexed citations

15.

Mirtsching, B., et al.. (2006). Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy. Journal of Clinical Oncology. 24(18_suppl). 8569–8569.

16.

Rader, Michael. (2006). Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.. PubMed. 20(5 Suppl 4). 16–21. 12 indexed citations

17.

Mirtsching, B., et al.. (2005). Impact of 1^st and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy: Preliminary results of FIRST, a prospective community-based study. Journal of Clinical Oncology. 23(16_suppl). 8118–8118. 2 indexed citations

18.

Theobald, Dale, et al.. (2000). Documentation of Indicators for Antidepressant Treatment and Response in an HMO Primary Care Population. Journal of Managed Care Pharmacy. 6(6). 494–498. 4 indexed citations

19.

Wadler, Scott, Edward L. Schwartz, Marc Goldman, et al.. (1989). Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.. Journal of Clinical Oncology. 7(12). 1769–1775. 271 indexed citations

20.

Hamburgh, Max, et al.. (1974). Malformations induced in offspring of crowded and parabiotically stressed mice. Teratology. 10(1). 31–37. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact